Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 28;12:6223. doi: 10.1038/s41467-021-26475-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a HBV-related deaths averted in each WHO region (mean and 95% credibility intervals) in the birth cohorts for years 2015 to 2050, in the scenario in which timely HepB-BD coverage is scaled up to ≥90% by 2030 in each country (the HepB-BD scale-up scenario) compared to the status quo HepB3 & HepB-BD scenario. Results are the sums within WHO regions from all modelled countries of n = 200 model outcomes resulting from 200 independent draws from the posterior distribution of each country. b Percentage of global total HBV-related deaths averted in the 2020 to 2030 birth cohorts that occurs in each country if timely HepB-BD coverage is scaled up to ≥90% by 2030 (the HepB-BD scale-up scenario) relative to the status quo HepB3 & HepB-BD scenario. The six WHO regions AFRO, EMRO, EURO, PAHO, SEARO, and WPRO are shown in Supplementary Fig. 1. HBV hepatitis B virus, HepB3 infant HBV vaccine series, timely HepB-BD timely birth dose, WHO World Health Organization.